OM:BOUL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Boule Diagnostics

Executive Summary

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. More Details


Snowflake Analysis

Adequate balance sheet with reasonable growth potential.

Share Price & News

How has Boule Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BOUL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.8%

BOUL

-6.0%

SE Medical Equipment

-2.0%

SE Market


1 Year Return

-0.6%

BOUL

20.1%

SE Medical Equipment

15.2%

SE Market

Return vs Industry: BOUL underperformed the Swedish Medical Equipment industry which returned 20.1% over the past year.

Return vs Market: BOUL underperformed the Swedish Market which returned 15.2% over the past year.


Shareholder returns

BOULIndustryMarket
7 Day-10.8%-6.0%-2.0%
30 Day-3.0%-0.3%2.9%
90 Day-15.9%5.2%4.9%
1 Year-0.6%-0.6%21.9%20.1%17.3%15.2%
3 Year-19.7%-20.9%71.3%51.6%34.7%20.2%
5 Year167.0%159.7%72.7%43.2%62.9%31.2%

Price Volatility Vs. Market

How volatile is Boule Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Boule Diagnostics undervalued compared to its fair value and its price relative to the market?

42.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BOUL (SEK51.3) is trading below our estimate of fair value (SEK89.05)

Significantly Below Fair Value: BOUL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BOUL is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.

PE vs Market: BOUL is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BOUL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BOUL is good value based on its PB Ratio (3.3x) compared to the SE Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Boule Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

103.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOUL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).

Earnings vs Market: BOUL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BOUL's is expected to become profitable in the next 3 years.

Revenue vs Market: BOUL's revenue (9.6% per year) is forecast to grow faster than the Swedish market (3.1% per year).

High Growth Revenue: BOUL's revenue (9.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BOUL's Return on Equity is forecast to be low in 3 years time (17.3%).


Next Steps

Past Performance

How has Boule Diagnostics performed over the past 5 years?

0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BOUL is currently unprofitable.

Growing Profit Margin: BOUL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BOUL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare BOUL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOUL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).


Return on Equity

High ROE: BOUL has a negative Return on Equity (-2.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Boule Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: BOUL's short term assets (SEK235.9M) exceed its short term liabilities (SEK169.8M).

Long Term Liabilities: BOUL's short term assets (SEK235.9M) exceed its long term liabilities (SEK97.6M).


Debt to Equity History and Analysis

Debt Level: BOUL's debt to equity ratio (39.4%) is considered satisfactory.

Reducing Debt: BOUL's debt to equity ratio has increased from 26.3% to 39.4% over the past 5 years.

Debt Coverage: BOUL's debt is well covered by operating cash flow (64.7%).

Interest Coverage: BOUL is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Boule Diagnostics's current dividend yield, its reliability and sustainability?

1.79%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BOUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BOUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BOUL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BOUL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: BOUL is not paying a notable dividend for the Swedish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BOUL's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Jesper Söderqvist (54 yo)

0.42

Tenure

Mr. Jesper Söderqvist, Ph.D., serves as Director at Arcoma AB since June 2020 and Board Member and Chief Executive Officer of Dekatria AB. He served as Chief Executive Officer of Arcoma AB until June 2020. ...


Leadership Team

NamePositionTenureCompensationOwnership
Jesper Söderqvist
President0.42yrno data0.077%
SEK 784.5k
Christina Rubenhag
Chief Financial Officer3yrsno data0.027%
SEK 277.2k
Eva Ekermann
Human Resources Director2.75yrsno data0.0027%
SEK 27.2k
Karen Bornstein
Head of Marketing16.75yrsno datano data
Michael Eliott
Head of Development - Reagents & Consumables28.75yrsno datano data
Christina Hugosson
Head of Development - Instruments & Systems13.75yrsno datano data
Michael Elliott
Senior Vice President of R&D OEM - CDSno datano data0.43%
SEK 4.4m
Debbie Herrera
Senior Vice President of Quality & Regulatory3.75yrsno datano data
Kiarash Farr
Senior Vice President of Commercial Operations2.58yrsno data0.010%
SEK 104.6k
Mikael Ekholm
Senior Vice President of Instrument Production0.67yrno datano data
Eduardo Pagani
Senior VP of Production of Consumablesno datano datano data
Bob Ariano
Sales & Marketing Director for USno datano datano data

3.0yrs

Average Tenure

56yo

Average Age

Experienced Management: BOUL's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jon Risfelt
Independent Director4.75yrskr235.00k0.046%
SEK 472.0k
Peter von Ehrenheim
Independent Chairman of the Board4.75yrskr470.00k0.46%
SEK 4.7m
Thomas Eklund
Independent Director6.75yrskr235.00k10.08%
SEK 102.3m
Charlotta Falvin
Independent Director2.75yrskr235.00kno data
Karin Dahllof
Independent Director5.75yrskr235.00k0.055%
SEK 557.0k

4.8yrs

Average Tenure

59yo

Average Age

Experienced Board: BOUL's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BOUL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Boule Diagnostics AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Boule Diagnostics AB (publ)
  • Ticker: BOUL
  • Exchange: OM
  • Founded: 1956
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.015b
  • Shares outstanding: 19.42m
  • Website: https://www.boule.com

Number of Employees


Location

  • Boule Diagnostics AB (publ)
  • Domnarvsgatan 4
  • Spånga
  • Stockholm County
  • 163 53
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOULOM (OMX Nordic Exchange Stockholm)YesCommon SharesSESEKJun 2011
0P4ZLSE (London Stock Exchange)YesCommon SharesGBSEKJun 2011
BDAB.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2011
BOULSBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBSEKJun 2011
8BDBST (Boerse-Stuttgart)YesCommon SharesDEEURJun 2011

Biography

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. It provides hematology analyzers, reagents, blood controls ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 21:45
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.